Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment

• Autor(a) principal: Gierlich, Piotr
• Data de Publicação: 2020
• Outros Autores: Mata, Ana I., Donohoe, Claire, Brito, Rui M. M., Senge, Mathias O., Silva, Lígia C. Gomes da
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/106489; https://doi.org/10.3390/molecules25225317
• topic: photodynamic therapy; cancer; drug delivery; active targeting; nanocarriers; Humans; Ligands; Nanoparticles; Neoplasms; Peptides; Photosensitizing Agents; Drug Delivery Systems

Photodynamic therapy (PDT) is a promising cancer treatment which involves a photosensitizer (PS), light at a specific wavelength for PS activation and oxygen, which combine to elicit cell death. While the illumination required to activate a PS imparts a certain amount of selectivity to PDT treatments, poor tumor accumulation and cell internalization are still inherent properties of most intravenously administered PSs. As a result, common consequences of PDT include skin photosensitivity. To overcome the mentioned issues, PSs may be tailored to specifically target overexpressed biomarkers of tumors. This active targeting can be achieved by direct conjugation of the PS to a ligand with enhanced affinity for a target overexpressed on cancer cells and/or other cells of the tumor microenvironment. Alternatively, PSs may be incorporated into ligand-targeted nanocarriers, which may also encompass multi-functionalities, including diagnosis and therapy. In this review, we highlight the major advances in active targeting of PSs, either by means of ligand-derived bioconjugates or by exploiting ligand-targeting nanocarriers.